Davis's Drug Guide
ruxolitinib (topical)
General
Pronunciation:
rux-oh-li-ti-nib
Trade Name(s)
- Opzelura
Ther. Class.
none assigned
Pharm. Class.
kinase inhibitors
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., et al. "Ruxolitinib (topical)." Davis's Drug Guide, 18th ed., F.A. Davis Company, 2023. www.drugguide.com/ddo/view/Davis-Drug-Guide/110926/all/ruxolitinib__topical_.
Vallerand AHA, Sanoski CAC, Quiring CC. Ruxolitinib (topical). Davis's Drug Guide. F.A. Davis Company; 2023. https://www.drugguide.com/ddo/view/Davis-Drug-Guide/110926/all/ruxolitinib__topical_. Accessed December 2, 2023.
Vallerand, A. H., Sanoski, C. A., & Quiring, C. (2023). Ruxolitinib (topical). In Davis's Drug Guide (18th ed.). F.A. Davis Company. https://www.drugguide.com/ddo/view/Davis-Drug-Guide/110926/all/ruxolitinib__topical_
Vallerand AHA, Sanoski CAC, Quiring CC. Ruxolitinib (topical) [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2023. [cited 2023 December 02]. Available from: https://www.drugguide.com/ddo/view/Davis-Drug-Guide/110926/all/ruxolitinib__topical_.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - ruxolitinib (topical)
ID - 110926
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
AU - Quiring,Courtney,
BT - Davis's Drug Guide
UR - https://www.drugguide.com/ddo/view/Davis-Drug-Guide/110926/all/ruxolitinib__topical_
PB - F.A. Davis Company
ET - 18
DB - Davis's Drug Guide
DP - Unbound Medicine
ER -